Market Cap: $1.65B
UL
UroGen Pharma Ltd.
URGN
NASDAQUSD
Market Cap: $1.65B
UroGen Pharma (Ticker: URGN) establishes a significant legal ground with its recent settlement and license agreement with Teva Pharmaceuticals concerning Jelmyto, its leading cancer treatment. This st…
UroGen Pharma Sees Growth in Innovative Urological Therapies UroGen Pharma announces a notable surge in performance, as reflected in its recently released Q4 earnings report. The company’s revenues fo…
UroGen Pharma Reports Strong Q4 Performance Driven by Innovative Therapies UroGen Pharma announces its fourth-quarter earnings, revealing revenues of $25 million, marking a 15% increase year-over-year…
UroGen Pharma Poised to Showcase Innovations in Urologic Therapies UroGen Pharma, a prominent player in the biopharmaceutical industry, is set to release its quarterly earnings report on March 2, 2026…
UroGen Pharma's Therapeutic Innovations: Addressing Unmet Needs in Urology UroGen Pharma is currently making strides in the biopharmaceutical sector with its focus on developing innovative therapies f…
UroGen Pharma: Pioneering Advances in Urological Treatments UroGen Pharma is making significant strides in the field of urology, particularly with its innovative approach to treating bladder cancer an…
UroGen Pharma Celebrates FDA Approval for ZUSDURI: A Milestone in Bladder Cancer Treatment UroGen Pharma Ltd (URGN) achieves a significant milestone with the recent approval of ZUSDURI by the U.S. Foo…
UroGen Pharma's Groundbreaking FDA Approval: A New Hope for Bladder Cancer Patients UroGen Pharma Ltd. achieves a significant milestone with the U.S. Food and Drug Administration's (FDA) approval of U…
UroGen Pharma Breakthrough: FDA Approval of URGN Zusduri for Bladder Cancer Treatment In a pivotal development for both UroGen Pharma Ltd. and the oncology community, the U.S. Food and Drug Administra…
UroGen Pharma Faces Analyst Downgrade Amidst Market Challenges UroGen Pharma Ltd., a company focused on innovative treatments for urological conditions, finds itself in a more cautious light following…
UroGen Pharma Faces Analyst Downgrade Amid Market Reassessment UroGen Pharma Ltd. stands at a critical juncture in its journey to develop innovative treatments for urological conditions, as evidenced…
UroGen Pharma Faces Downgrade Amidst Evolving Market Dynamics UroGen Pharma Ltd. finds itself at a pivotal moment as analyst Raghuram Selvaraju of HC Wainwright & Co. downgrades the company's rating f…
UroGen Pharma Faces Regulatory Setback with UGN-102 UroGen Pharma Ltd. encounters a significant challenge as the Oncologic Drugs Advisory Committee (ODAC) of the Food and Drug Administration (FDA) vot…
UroGen Pharma Faces Regulatory Setback Over UGN-102: Implications for Oncological Drug Development UroGen Pharma Ltd. is currently grappling with the fallout from a recent decision by the Oncologic Dr…
UroGen Pharma Faces Regulatory Setback with UGN-102 UroGen Pharma Ltd. confronts a significant challenge following the recent decision by the Oncologic Drugs Advisory Committee (ODAC) of the Food and…
UroGen Pharma's UGN-102 Shows Promising Efficacy in Bladder Cancer Treatment UroGen Pharma Ltd. announces significant advancements in the treatment of low-grade intermediate-risk non-muscle-invasive b…
UroGen Pharma's JELMYTO® Shows Promising Long-Term Efficacy in Treating LG-UTUC UroGen Pharma Ltd. has announced encouraging results from a long-term follow-up study of its innovative treatment, JELMY…
UroGen Pharma Reports Long-Term Efficacy of JELMYTO in Treating Low-Grade Upper Tract Urothelial Cancer UroGen Pharma Ltd. has unveiled promising findings from a long-term follow-up study regarding it…
UroGen Pharma Showcases Promising Long-Term Results for JELMYTO at SUO Annual Meeting UroGen Pharma Ltd., a biotechnology company dedicated to developing innovative treatments for urothelial and speci…
UroGen Pharma's Innovative Leap in Bladder Cancer Treatment UroGen Pharma Ltd. stands at the forefront of innovation in the treatment of urothelial cancers, particularly with its recent announcement r…